GlassScriptPhysician profile
Fatema S Uddin
NPI 1144430893
$56,162.38
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.96 · 2020: $12.85 · 2021: $49.77 · 2022: $19K · 2023: $34K · 2024: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Food and Beverage: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,746.69 |
| Food and Beverage | $119.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $55,857.41 | 2022-2024 | |
| Braintree Laboratories, INC. | $66.07 | 2020-2024 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.65 | 2019-2022 | |
| Madrigal Pharmaceuticals | $24.92 | 2024 | Resmetirom |
| Regeneron Healthcare Solutions, INC. | $24.50 | 2023 | Dupixent |
| Janssen Biotech, INC. | $23.55 | 2023 | Stelara, Remicade, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $20.45 | 2022 | |
| Abbvie INC. | $17.09 | 2022 | |
| Ardelyx, INC. | $16.55 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.05 | 2019 | |
| Redhill Biopharma INC. | $13.78 | 2023 | Aemcolo, Talicia, Movantik |
| Celgene Corporation | $12.91 | 2022 | |
| Intercept Pharmaceuticals, INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatema Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.